Maria A Hawkins

List of Publications by Citations

Source: https://exaly.com/author-pdf/5587273/maria-a-hawkins-publications-by-citations.pdf
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

129 papers	2,990 citations	26 h-index	51 g-index
195 ext. papers	3,692 ext. citations	2.9 avg, IF	5.02 L-index

#	Paper	IF	Citations
129	Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. *Journal of Clinical Oncology*, **2008**, 26, 657-64	2.2	446
128	Stereotactic body radiotherapy for oligometastases. *Lancet Oncology, The*, **2013**, 14, e28-37	21.7	326
127	Radiation therapy for hepatocellular carcinoma: from palliation to cure. *Cancer*, **2006**, 106, 1653-63	6.4	196
126	Reproducibility of liver position using active breathing coordinator for liver cancer radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 751-9	4	171
125	Clinical development of new drug-radiotherapy combinations. *Nature Reviews Clinical Oncology*, **2016**, 13, 627-42	19.4	162
124	Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. *British Journal of Surgery*, **2013**, 100, 1009-14	5.3	123
123	UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy. *Clinical Oncology*, **2018**, 30, 5-14	2.8	109
122	Assessment of residual error in liver position using kV cone-beam computed tomography for liver cancer high-precision radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2006**, 66, 610-9	4	94
121	The Impact of Cardiac Radiation Dosimetry on Survival After Radiation Therapy for Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 51-60	4	42
120	Improving image-guided target localization through deformable registration. *Acta Oncologica*, **2008**, 47, 1279-85	3.2	42
119	Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. *Lancet Oncology, The*, **2021**, 22, 98-106	21.7	40
118	ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. *Radiotherapy and Oncology*, **2016**, 119, 306-11	5.3	39
117	Stereotactic body radiotherapy for liver metastases. *Clinical Oncology*, **2015**, 27, 307-15	2.8	37
116	Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. *Clinical Oncology*, **2008**, 20, 221-6	2.8	35
115	Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19. *Radiotherapy and Oncology*, **2020**, 148, 194-200	5.3	34
114	miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. *Oncotarget*, **2016**, 7, 12672-81	3.3	32
113	Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. *American Journal of Clinical Nutrition*, **2017**, 106, 849-857	7	31

112	The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, E164-E165	4	30
111	Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancer. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, 423-9	4	29
110	Set-up errors in radiotherapy for oesophageal cancers--is electronic portal imaging or conebeam more accurate?. *Radiotherapy and Oncology*, **2011**, 98, 249-54	5.3	29
109	Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. *Radiotherapy and Oncology*, **2016**, 121, 232-238	5.3	29
108	Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans. *Clinical Oncology*, **2013**, 25, 155-61	2.8	28
107	The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. *British Journal of Radiology*, **2009**, 82, 321-7	3.4	27
106	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. *European Journal of Cancer*, **2017**, 74, 38-46	7.5	26
105	A tumor control probability model for anal squamous cell carcinoma. *Radiotherapy and Oncology*, **2015**, 116, 192-6	5.3	26
104	Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization. *Frontiers in Oncology*, **2017**, 7, 153	5.3	26
103	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. *International Journal of Radiation Oncology Biology Physics*, **2018**, 101, 1202-1211	4	25
102	Quantification of organ motion during chemoradiotherapy of rectal cancer using cone-beam computed tomography. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, e431-8	4	24
101	NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. *BMC Cancer*, **2015**, 15, 48	4.8	23
100	Cone beam computed tomography-derived adaptive radiotherapy for radical treatment of esophageal cancer. *International Journal of Radiation Oncology Biology Physics*, **2010**, 77, 378-83	4	23
99	Oesophageal Chemoradiotherapy in the UK--current practice and future directions. *Clinical Oncology*, **2013**, 25, 368-77	2.8	22
98	Volumetric modulated arc therapy planning for distal oesophageal malignancies. *British Journal of Radiology*, **2012**, 85, 44-52	3.4	22
97	An Analysis of Plan Robustness for Esophageal Tumors: Comparing Volumetric Modulated Arc Therapy Plans and Spot Scanning Proton Planning. *International Journal of Radiation Oncology Biology Physics*, **2016**, 95, 199-207	4	22
96	Initial Results from the Royal College of RadiologistsRUK National Audit of Anal Cancer Radiotherapy 2015. *Clinical Oncology*, **2017**, 29, 188-197	2.8	20
95	Pelvic re-irradiation using stereotactic ablative radiotherapy (SABR): A systematic review. *Radiotherapy and Oncology*, **2017**, 125, 213-222	5.3	20

94	Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost. *British Journal of Radiology*, **2013**, 86, 20120466	3.4	20
93	Motion artifact correction in free-breathing abdominal MRI using overlapping partial samples to recover image deformations. *Magnetic Resonance in Medicine*, **2009**, 62, 440-9	4.4	20
92	Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. *The Lancet Gastroenterology and Hepatology* , **2020**, 5, 765-775	18.8	19
91	Size does matter: can we reduce the radiotherapy field size for selected cases of anal canal cancer undergoing chemoradiation?. *Clinical Oncology*, **2009**, 21, 376-9	2.8	18
90	HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. *Breast*, **2008**, 17, 661-5	3.6	18
89	Correlation of F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. *Clinical Oncology*, **2017**, 29, 370-377	2.8	17
88	Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer. *Radiotherapy and Oncology*, **2015**, 117, 246-51	5.3	16
87	Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study. *Cancer*, **2018**, 124, 2001-2009	6.4	15
86	Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial. *BMC Cancer*, **2012**, 12, 530	4.8	15
85	The role of radiotherapy and chemoradiation in the management of primary liver tumours. *Clinical Oncology*, **2014**, 26, 569-80	2.8	14
84	Cone beam CT verification for oesophageal cancer - impact of volume selected for image registration. *Acta Oncologica*, **2011**, 50, 1183-90	3.2	14
83	Novel prostate brachytherapy technique: improved dosimetric and clinical outcome. *Radiotherapy and Oncology*, **2008**, 88, 121-6	5.3	14
82	ESTRO ACROP guidelines for target volume definition in pancreatic cancer. *Radiotherapy and Oncology*, **2021**, 154, 60-69	5.3	14
81	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. *British Journal of Cancer*, **2020**, 123, 709-713	8.7	13
80	Challenges in using □E-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer. *Radiation Oncology*, **2014**, 9, 146	4.2	13
79	Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 729-737	4	13
78	Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data. *Radiotherapy and Oncology*, **2017**, 123, 431-437	5.3	12
77	The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies. *Clinical Oncology*, **2014**, 26, 581-96	2.8	12

76	Dynamic shape instantiation for intra-operative guidance. *Lecture Notes in Computer Science*, **2010**, 13, 69-76	0.9	12
75	Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit. *Clinical Oncology*, **2018**, 30, 280-284	2.8	11
74	A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the ISPARCR trial protocol. *BMC Cancer*, **2016**, 16, 728	4.8	11
73	Risk factors for vertebral compression fracture after spine stereotactic body radiation therapy: Long-term results of a prospective phase 2 study. *Radiotherapy and Oncology*, **2019**, 141, 62-66	5.3	11
72	Risk-adapted strategy partial liver irradiation for the treatment of large volume metastatic liver disease. *Acta Oncologica*, **2014**, 53, 702-6	3.2	11
71	Systematic review and meta-analysis of small bowel dose-volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy. *Radiotherapy and Oncology*, **2019**, 138, 38-44	5.3	9
70	UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. *European Journal of Cancer*, **2020**, 128, 7-16	7.5	9
69	Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for dose calculation in treatment of oesophageal cancer: effects on modelling tumour control probability. *Radiation Oncology*, **2014**, 9, 286	4.2	9
68	214 A trial in design: CORE Conventional Care or Radioablation in the treatment of Extracranial metastases. *Lung Cancer*, **2014**, 83, S79	5.9	9
67	Conformity analysis to demonstrate reproducibility of target volumes for Margin-Intense Stereotactic Radiotherapy for borderline-resectable pancreatic cancer. *Radiotherapy and Oncology*, **2016**, 121, 86-91	5.3	9
66	Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer. *Radiotherapy and Oncology*, **2020**, 143, 19-23	5.3	9
65	Respiratory Gated Cone-Beam CT Volumetric Imaging for External Beam Radiotherapy. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, S27-S28	4	8
64	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). *Radiation Oncology*, **2020**, 15, 151	4.2	7
63	Intravenous contrast-enhanced cone beam computed tomography (IVCBCT) of intrahepatic tumors and vessels. *Advances in Radiation Oncology*, **2016**, 1, 43-50	3.3	7
62	Is There a Role for an 18F-fluorodeoxyglucose-derived Biological Boost in Squamous Cell Anal Cancer?. *Clinical Oncology*, **2019**, 31, 72-80	2.8	6
61	Stereotactic Body Radiation Therapy Reirradiation for Locally Recurrent Rectal Cancer: Outcomes and Toxicity. *Advances in Radiation Oncology*, **2020**, 5, 1311-1319	3.3	6
60	Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). *BMC Cancer*, **2019**, 19, 121	4.8	6
59	Early stage anal margin cancer: towards evidence-based management. *Colorectal Disease*, **2019**, 21, 387-391	2.1	5

58	Chemoradiotherapy of locally-advanced non-small cell lung cancer: Analysis of radiation dose-response, chemotherapy and survival-limiting toxicity effects indicates a low □/□ ratio. *Radiotherapy and Oncology*, **2020**, 143, 58-65	5.3	5
57	A systematic review of health economic evaluations of proton beam therapy for adult cancer: Appraising methodology and quality. *Clinical and Translational Radiation Oncology*, **2020**, 20, 19-26	4.6	5
56	The Evolving Role of Radiation Therapy in the Treatment of Biliary Tract Cancer. *Frontiers in Oncology*, **2020**, 10, 604387	5.3	5
55	Driving developments in UK oesophageal radiotherapy through the SCOPE trials. *Radiation Oncology*, **2019**, 14, 26	4.2	4
54	The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: a radiobiological investigation. *Radiation Oncology*, **2015**, 10, 236	4.2	4
53	Feasibility of Free-breathing Respiratory Gated Liver Radiotherapy with MRI-derived Models. *Clinical Oncology*, **2007**, 19, S13	2.8	4
52	On-trial radiotherapy quality assurance in NeoSCOPE: A randomised phase II trial of chemoradiotherapy in oesophageal cancer.. *Journal of Clinical Oncology*, **2016**, 34, 119-119	2.2	4
51	Stereotactic body radiotherapy for moderately central and ultra-central oligometastatic disease: Initial outcomes. *Technical Innovations and Patient Support in Radiation Oncology*, **2020**, 13, 24-30	1.9	4
50	NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer. *Cancer Genetics*, **2020**, 248-249, 1-10	2.3	4
49	Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT). *Radiotherapy and Oncology*, **2016**, 121, 92-97	5.3	4
48	Challenges in implementing model-based phase I designs in a grant-funded clinical trials unit. *Trials*, **2017**, 18, 620	2.8	3
47	A Randomised Trial of Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases. *Clinical Oncology*, **2018**, 30, e64	2.8	3
46	Stomach Dose-Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. *Clinical Oncology*, **2018**, 30, 418-426	2.8	3
45	Stepwise Multicenter Introduction of Intensity Modulated Radiation Therapy for Anal Cancer in the United Kingdom: From Consensus Guidance to Large-Scale Prospective Audit, Prior to Future Clinical Trials. *International Journal of Radiation Oncology Biology Physics*, **2016**, 96, S105-S106	4	3
44	Comparison of Breath Hold Cone Beam CT and Orthogonal Image Guided Radiotherapy for Liver Cancer. *International Journal of Radiation Oncology Biology Physics*, **2005**, 63, S555-S556	4	3
43	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe.. *European Journal of Cancer*, **2022**, 164, 18-29	7.5	3
42	Unwrapping 3D complex hollow organs for spatial dose surface analysis. *Medical Physics*, **2016**, 43, 6009	4.4	3
41	Impact of abdominal compression on setup error and image matching during radical abdominal radiotherapy. *Technical Innovations and Patient Support in Radiation Oncology*, **2019**, 12, 28-33	1.9	3

40	Prospective Review of Outlining in the UK NeoSCOPE Esophageal Trial. *International Journal of Radiation Oncology Biology Physics*, **2014**, 90, S733	4	2
39	Cone beam CT verification for active breathing control (ABC)-gated radiotherapy for lung cancer. *Acta Oncologica*, **2014**, 53, 716-9	3.2	2
38	Penile Bulb Dosimetry Impact of Prostate Brachytherapy Implant Technique. *Clinical Oncology*, **2007**, 19, S7-S8	2.8	2
37	Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy. *Radiotherapy and Oncology*, **2020**, 151, 280-286	5.3	2
36	Cardiac-sparing radiotherapy for locally advanced non-small cell lung cancer. *Radiation Oncology*, **2021**, 16, 95	4.2	2
35	OC-0057: Cardiotoxicity and cardiac substructure dosimetry in doseescalated lung radiotherapy. *Radiotherapy and Oncology*, **2016**, 119, S24-S25	5.3	2
34	CORE: A randomised trial of COventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases. *Lung Cancer*, **2018**, 115, S85-S86	5.9	2
33	NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch. *Antioxidants*, **2021**, 10,	7.1	2
32	Session 3: Beyond the boundaries of Total Mesorectal Excision - where surgeons fear to tread. *Colorectal Disease*, **2018**, 20 Suppl 1, 61-64	2.1	1
31	Normal tissue sparing with respiratory adapted volumetric modulated arc therapy for distal oesophageal and gastro-oesophageal tumours. *Acta Oncologica*, **2014**, 53, 149-54	3.2	1
30	Nonsurgical management of esophageal adenocarcinoma. *Clinical Colorectal Cancer*, **2011**, 10, 165-70	3.8	1
29	Patient and tumor characteristics impacting on lymph node metastases rate (LNMR) in squamous cell carcinoma of the anal canal and margin (SCCA) using data from the NCRI randomized phase III ACT II trial: Implications for radiotherapy target volume.. *Journal of Clinical Oncology*, **2014**, 32, 4032-4032	2.2	1
28	NeoSCOPE: A phase II randomized comparison of neoadjuvant oxaliplatin/capecitabine versus carboplatin/paclitaxel-based chemoradiation in operable esophageal cancer.. *Journal of Clinical Oncology*, **2014**, 32, TPS4144-TPS4144	2.2	1
27	NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2016**, 34, 3-3	2.2	1
26	Image-guided radiotherapy for esophageal cancer. *Imaging in Medicine*, **2012**, 4, 515-525	1	1
25	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. *Radiotherapy and Oncology*, **2021**, 165, 119-125	5.3	1
24	Patient and Public Involvement Refines the Design of ProtOeus: A Proposed Phase II Trial of Proton Beam Therapy in Oesophageal Cancer. *Patient*, **2021**, 14, 545-553	3.7	1
23	Salvage surgery with abdominoperineal excision of the rectum (APER) following loco-regional failure after chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) and the impact on long-term outcomes: Results of ACT II.. *Journal of Clinical Oncology*, **2016**, 34, 3523-3523	2.2	1

22	Stereotactic radiotherapy and oligometastases - AuthorsR reply. *Lancet Oncology, The*, **2021**, 22, e133	21.7	1
21	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. *European Journal of Cancer*, **2021**, 153, 153-161	7.5	1
20	PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.. *Journal of Clinical Oncology*, **2019**, 37, TPS4166-TPS4166	2.2	0
19	SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. *Radiotherapy and Oncology*, **2021**, 155, 278-284	5.3	0
18	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. *Radiotherapy and Oncology*, **2021**, 164, 104-114	5.3	0
17	A Phase II trial of Higher RadiOtherapy Dose In The Eradication of early rectal cancer (APHRODITE): protocol for a multicentre, open-label randomised controlled trial.. *BMJ Open*, **2022**, 12, e049119	3	0
16	Four-dimensional Computed Tomography Contouring Variability in Stereotactic Body Radiotherapy of Non-resectable Biliary Tract Cancer. *Clinical Oncology*, **2017**, 29, e137	2.8	
15	Effect of anaemia prevention on survival and local control in oesophageal cancers treated with chemoradiotherapy. *Clinical Oncology*, **2012**, 24, 454-5	2.8	
14	Case 23-2005: a man with a mass in the liver. *New England Journal of Medicine*, **2005**, 353, 2195-7; author reply 2195-7	59.2	
13	SPARC: A phase-I trial of pre-operative margin-intensified stereotactic radiotherapy for pancreatic cancer at high risk of positive resection margins.. *Journal of Clinical Oncology*, **2018**, 36, TPS536-TPS536	2.2	
12	Outcomes following stereotactic body radiotherapy (SBRT) in locally recurrent rectal cancer (LRRC) in a previously irradiated pelvis.. *Journal of Clinical Oncology*, **2019**, 37, 640-640	2.2	
11	Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).. *Journal of Clinical Oncology*, **2019**, 37, 557-557	2.2	
10	ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)M Mechanism and clinical outcomes.. *Journal of Clinical Oncology*, **2015**, 33, e15279-e15279	2.2	
9	TH-AB-BRB-11: A Method of Unwrapping 3D Complex Hollow Organs for Spatial Dose Surface Analysis. *Medical Physics*, **2015**, 42, 3706-3706	4.4	
8	WE-AB-202-10: Modelling Individual Tumor-Specific Control Probability for Hypoxia in Rectal Cancer. *Medical Physics*, **2016**, 43, 3796-3796	4.4	
7	SU-D-BRA-06: Duodenal Interfraction Motion with Abdominal Compression. *Medical Physics*, **2016**, 43, 3340-3340	4.4	
6	Does phase I radiotherapy dose of 30.6Gy in 17 fractions provide adequate microscopic nodal disease control in squamous cell carcinoma of the anus?. *Journal of Clinical Oncology*, **2012**, 30, 588-588	2.2	
5	MO-F-WAB-01: A Comparison of 20 Free Breathing Versus AlignRT Based DIBH Breast Treatments. *Medical Physics*, **2013**, 40, 409-410	4.4	

List of Publications

4	Volumetric analysis of anal cancer relapses following radical chemoradiation.. *Journal of Clinical Oncology*, **2014**, 32, 576-576	2.2
3	Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". *British Journal of Cancer*, **2021**, 124, 679-680	8.7
2	Session 3: Intra-operative radiotherapy - creating new surgical boundaries. *Colorectal Disease*, **2018**, 20 Suppl 1, 65-75	2.1
1	A decision tool for radiographer-led abdominal image-guided stereotactic ablative body radiotherapy - Experience from a single institution. *Technical Innovations and Patient Support in Radiation Oncology*, **2021**, 19, 33-36	1.9